OHSU

IRB #

IRB00009531

Title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to find out if vandetanib (the study drug), is safe and has beneficial effects in people with papillary or poorly differentiated thyroid cancer that is advanced or metastatic and unsutibale for radioiodine (RAI) therapy.

Medical Condition(s)

Papillary or poorly differentiated thyroid cancer that is advanced or metastatic.

Eligibility Criteria

1. Adults aged 18 years or above.
2. Histologically confirmed diagnosis of metastatic and/or unresectable papillary or poorly differentiated thyroid cancer that is unsuitable for RAI therapy.
3. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression or unacceptable side effect.

Minors Included

No

Contact

Tracy Walker, RN (503) 346-1183 or trials@ohsu.edu

Sponsor

AstraZeneca Pharmaceuticals, LP

Recruitment End

12/01/2014

Compensation Provided

No


Go Back